Dendreon Corporation (DNDN), a Washington state based biotechnology company saw it’s shares plummet off a cliff a few weeks ago, after pulling the plug on it’s sales forecast for it’s flagship cancer therapy Provenge. ┬áThis was done after poor initial sales due to the high cost (in the $100k ballpark) of the therapy, and the